COR Cortex Pharmaceuticals,

NI Research today announced the release of the November issue of NeuroInvestment, featuring a review of pharmacologic therapeutics for addiction. The interface of the biological and sociocultural factors involved in substance abuse is reviewed for addictions to alcohol, opioids, stimulants (methamphetamines and cocaine), and nicotine.

Programs under development by over 25 companies are included in this review. They range from the depot therapeutics already marketed or under development by companies like Alkermes, Titan Pharmaceuticals, and Elbion, to novel pharmaceutical approaches from Synosia Therapeutics and Catalyst Pharmaceuticals.

The October issue also considers the evaporating prospects for Vanda Pharmaceuticals; the failure of Avigen's AV650; Neurogen's success with aplindore; and the ramifications of the Phase II respiratory depression success demonstrated by Cortex Pharmaceuticals (AMEX: COR). It also includes the first in an occasional series of reviews of Big Pharma companies as corporate partners, with an evaluation of Pfizer.

NeuroInvestment is the independent, monthly review of the neurotherapeutics area. Its reputation has been built via thirteen years of objective, insightful, and critical coverage of the neurotherapeutics field. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month trial is US$600.

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides inlicensing consultation and custom services. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

Contact: NI Research P.O. Box 1028 Cardiff CA 92007 760.230.2581 Email Contact Email Contact Website: www.niresearch.com